How to launch a medical device in the US comes down to four decisions, made in order. First, decide whether the product is a medical device at all, which depends on what you claim it does. Second, if it is, find its FDA class and pathway: exempt, 510(k), De Novo or premarket approval (PMA).
Third, keep every piece of marketing inside the intended use FDA reviewed. Fourth, pick one buyer and build demand around the clearance date, remembering that a device under 510(k) review can be advertised but cannot take orders.
Blazon has seen that order play out across 500+ product launches, including Pillo Health, later acquired by Stanley Black & Decker. Health devices rarely stall on the engineering. They stall on one line of copy that turned a wellness gadget into an unauthorized medical device, or a cleared device into a misbranded one.
This is not legal advice. Every rule below links to its source, and your regulatory counsel has the final word.
The claim decides whether it is a medical device
Under section 201(h) of the Federal Food, Drug, and Cosmetic Act, a device is a product intended to diagnose, cure, mitigate, treat or prevent disease, or to affect the structure or function of the body. The word that matters is intended, and FDA reads intent from what you say: the label, the website, the ads and the app screens.
Two wearables show how far apart the same kind of sensor can land. Apple took its hypertension notification feature through FDA. The 510(k) clearance, dated September 11, 2025, cleared it as a Class II device for over-the-counter use by adults 22 and over who have not been diagnosed with hypertension, and says it does not replace traditional diagnosis.
Whoop positioned its Blood Pressure Insights feature as wellness. On July 14, 2025, FDA sent the company a warning letter saying blood pressure estimation is not low risk and the product's disclaimers did not change that. The letter records that Whoop intended to keep marketing the feature without FDA authorization.
FDA's January 2026 wellness guidance later set conditions under which non-invasive blood pressure estimates can count as wellness. The lesson holds either way: the marketing team writes the intended use, whether it knows it or not.
The general wellness lane: no FDA submission, strict words
FDA's guidance General Wellness: Policy for Low Risk Devices, reissued on January 6, 2026, covers products FDA does not intend to examine as devices. The intended use must be general wellness only, and the product must be low risk.
Wellness claims come in two kinds. The first supports a general state of health with no reference to disease: weight management, physical fitness, relaxation or stress management, mental acuity, self-esteem, sleep management and sexual function.
The second links a healthy lifestyle to reducing the risk or impact of a well-understood chronic condition, such as heart disease, high blood pressure or type 2 diabetes. The guidance's own example: a product that "promotes physical activity, which, as part of a healthy lifestyle, may help reduce the risk of high blood pressure."
Low risk means not invasive, not implanted and not using technology such as lasers or radiation that needs regulatory controls to be safe.
The 2026 version adds the section every wearable founder should read. A product estimating blood pressure, oxygen saturation, blood glucose or heart rate variability can still be wellness if the output serves wellness only.
It loses that status when its labeling, advertising, interface or features reference a specific disease or diagnostic threshold, send alerts that recommend clinical action, give treatment guidance, claim clinical accuracy or "medical grade" performance, or present it as a substitute for an FDA-authorized device. A note suggesting a healthcare professional is allowed, as long as it names no disease and calls nothing abnormal.
Read that list as a copywriter. "Medical grade" and "clinical accuracy" are the phrases that sell a health gadget, and exactly the phrases that take it out of the wellness lane.
In a health launch claims audit, Blazon writes the wellness version of every headline first, then checks whether the product still sells on it. It usually does, and the FTC evidence rules below still apply.
The regulated pathways: Class I, 510(k), De Novo and PMA
If the product is a device, FDA assigns it to one of three classes by risk, Class I lowest and Class III highest. FDA says about 74% of Class I device types are exempt from premarket notification.
Search FDA's classification database for a similar device to find your product code. If the answer is unclear, a 513(g) request gets a formal determination from FDA for a user fee, reduced for small businesses.
| Path | Fits | What FDA looks at | What you can say after | FDA's stated timing |
|---|---|---|---|---|
| General wellness | Low-risk, wellness-only claims | Nothing submitted | No FDA status | None |
| Class I exempt | About 74% of Class I types | Registration, listing, general controls | No clearance or approval claim | None |
| 510(k) | Most Class II devices with a predicate | Substantial equivalence to a legally marketed device | "FDA cleared" | Decision usually within 90 days |
| De Novo | Novel devices with no predicate | A new risk-based classification | De Novo "granted" | Goal of 150 review days |
| PMA | Class III devices | Valid scientific evidence of safety and effectiveness | "FDA approved" | No figure on FDA's PMA page |
A 510(k) needs the same intended use as its predicate. FDA asks for it at least 90 days before you offer the device for sale, and you cannot market until FDA's order clears it.
De Novo is for a novel device with no predicate. A grant creates a new classification regulation, and the device can then be the predicate for later 510(k)s. Apple's hypertension feature is that chain in action: its predicate was Viz HCM, a device authorized through De Novo.
PMA is FDA's most stringent device application, for Class III, and needs sufficient valid scientific evidence that the device is safe and effective for its intended use.
Talk to FDA before you file. The Q-Submission program, updated in May 2025, lets you request written feedback or a meeting on a planned submission.
If the device treats or diagnoses a life-threatening or irreversibly debilitating condition, look at the Breakthrough Devices Program. Designation buys prioritized review, not authorization: as of June 30, 2026, FDA counted 1,320 designations and 210 marketing authorizations. Never market the designation like a clearance.
Selling also brings standing obligations: annual registration and device listing with a user fee, manufacturing under the Quality Management System Regulation (21 CFR Part 820, in force since February 2, 2026), and adverse event reporting under 21 CFR Part 803.
What you can and cannot say before clearance
This is where most launch plans break, because consumer playbooks assume you sell before you ship.
FDA's compliance policy on commercial distribution and the 510(k) says a firm may advertise or display a device that is the subject of a pending 510(k). It may not take orders, or be prepared to take orders, that might result in contracts of sale, unless limited to research or investigational use. The policy addresses pending 510(k)s, so a device headed for De Novo or PMA needs its own answer from counsel.
A device still in clinical study is tighter again. 21 CFR 812.7 bars the sponsor from promoting or test marketing it, calling it safe or effective for the purpose under study, or charging subjects more than cost.
That kills The Deposit Test for regulated devices. Blazon uses refundable deposits to prove demand on consumer products, because a person who will not put down a small deposit will not pay full price on launch day. A device waiting on its 510(k) cannot take that money.
So build the signals you are allowed to build: an email waitlist with no order attached, clinicians willing to be named advisers, sites that want to run your study, and press about the problem with no performance claims for the device. Have counsel read the signup page before it goes live.
A wellness product has none of these limits. Deposits beat free signups there, as Blazon's waitlist strategy sets out, and the Shopify pre-orders playbook covers the federal rule on ship dates and refunds.
What you can say after clearance
Clearance is permission to sell the device for the indications FDA reviewed, and everything you say has to stay inside them. Three rules catch founders most often.
Say cleared, not approved. A 510(k) device is "FDA cleared." Under 21 CFR 807.97, clearance does not denote official FDA approval, and any representation that creates that impression is misbranding.
The FTC's Health Products Compliance Guidance shows what that costs, using an ab belt cleared as a Class II device to stimulate and strengthen healthy muscle. Its infomercial repeated "FDA Approved" next to waist-loss claims, and the FTC calls that deceptive because it implied FDA had found the belt works for weight loss.
New uses need new submissions. A major change in intended use requires a new 510(k) under 21 CFR 807.81. A product cleared for one claim and marketed for a bigger one is, in FDA's eyes, a different device.
The evidence has to match the claim. The FTC requires competent and reliable scientific evidence for health claims, and its guidance says health benefits generally need randomized, controlled human clinical trials. It judges the net impression of the whole ad, implied claims included.
Testimonials reporting results more dramatic than users can generally expect are likely deceptive, and a "results not typical" line does not fix them.
Under the FTC guidance, FDA has primary responsibility for labeling claims and the FTC for advertising claims. FDA also regulates advertising for restricted devices under 21 U.S.C. 352(q) and (r).
Two more FTC rules land on device marketing. The Consumer Reviews and Testimonials rule, announced in August 2024, bans fake and AI-generated reviews, paying for reviews of a particular sentiment, undisclosed insider reviews and review suppression, with civil penalties for knowing violations.
The Health Breach Notification Rule, updated in April 2024, covers health apps and connected devices outside HIPAA. It counts sharing health data without the user's authorization as a breach, which puts the ad pixel inside a health app on counsel's checklist.
Pick the buyer before you pick the channel
A medical device can have four different buyers, and each one wants different proof.
Consumers buying a wellness device want to see it work for someone like them. This is the closest to a normal consumer launch: a store, paid social, creators and reviews, inside the ad platforms' health policies.
Consumers buying a cleared over-the-counter device sit between two worlds. Dexcom's Stelo was cleared on March 5, 2024 as the first over-the-counter continuous glucose monitor, for adults 18 and over who do not use insulin, bought without the involvement of a health care provider.
The claims still follow the clearance: FDA noted Stelo is not for people with problematic hypoglycemia, because it does not alert users to dangerous lows. A direct channel does not widen what you can say.
Clinicians want evidence, workflow fit and a peer who has used the device. Payments or anything of value you give physicians may be reportable to CMS Open Payments, which publishes them in a public database.
Payers decide whether anyone else pays, and FDA authorization is not coverage. FDA runs a Payor Communication Task Force to shorten the gap between market authorization and coverage decisions.
Medicare's TCET pathway aims to finalize national coverage within six months of FDA authorization, but only for up to five Breakthrough-designated candidates a year. Everyone else goes the long way, so a reimbursed device needs a cash plan that does not assume payers on day one.
Retail buyers want proof the device already sells, so a direct channel first usually produces the numbers that open retail.
Pick one buyer for the first launch. Selling to clinicians and consumers in the same year means two evidence packages, two sets of claims and two budgets.
Build the evidence and the audience together
Most device teams design the study, get the data, then ask marketing what it can say. Run it the other way.
Write the claim you want in the ad first, then design the evidence that supports it for the FDA reviewer and the FTC. A study proving something nobody will pay for is wasted money. A headline with no study behind it is a warning letter in waiting.
Build the audience alongside, inside the rules above, so the waitlist, the clinician advisers and the press relationships all exist on the day FDA's letter arrives. For a device pending clearance, stop Blazon's demand validation ladder at the email rung until the clearance lands.
Medtech PR: the problem is the story, the clearance is the proof
Clearance day is the Launch Moment. FDA publishes its 510(k) clearances, so have the release, founder interviews and embargoed briefings ready before the letter arrives.
Pillo shows the other half of the work. Pillo is a home-health robot that helps people manage their medication, a new kind of household device. Blazon shaped its launch story and PR around the three questions a new category has to answer fast: what is it, where does it fit in my day, and why should I care.
The answers were written in plain, human terms so Pillo felt approachable rather than clinical. The launch reached technology and health press around the world, with 120+ press features, and the product went on to $2.5M in sales before Stanley Black & Decker acquired the company.
Press materials are promotion, held to the same claims rules as an ad. Pitch clinical press with the data and consumer press with the human problem, and keep the numbers identical. Blazon's press kit and outreach system covers the mechanics, and the PR service is where Blazon runs it.
The launch sequence, from claims map to clearance day
Before filing. Settle the intended use and write the claims map: every claim you want, the evidence each needs, and which lane it fits. Confirm the classification, request a Pre-Sub, and build a brand and story that do not depend on performance claims.
During review. Advertise and display within the pending-510(k) policy, with no orders. Grow the waitlist, line up clinician advisers, prepare press for clearance day, and build the store with checkout switched off.
Clearance day. Turn on sales, announce the exact cleared indication using the word "cleared," and give the waitlist the first chance to buy. Confirm registration and listing before the first unit ships.
After launch. Report adverse events, keep every new ad inside the cleared indications, and treat any new claim as a regulatory question first. The product launch timeline and hardware launch guide cover the manufacturing and fulfillment side.
How Blazon works on health tech launches
Blazon runs the commercial side of wellness and health tech launches: positioning, a claims audit on every line of copy, brand, the Shopify store, PR and paid media built to pass the ad platforms' health policies. Blazon does not take on pharmaceuticals or Class II and Class III medical devices, where a specialist regulatory agency is required.
The health and wellness launch agency page covers healthtech devices, wearables and wellness products. The hardware launch agency covers build to ship, and the product launch agency page sets out the full program.
FDA decides whether your device can be sold. Your copy decides what your device is, and FDA reads the copy.
Frequently asked questions
What is the difference between FDA cleared and FDA approved?
"FDA cleared" means FDA found a device substantially equivalent to a legally marketed device through a 510(k). "FDA approved" applies to Class III devices that passed premarket approval, FDA's most stringent review. Novel devices authorized through De Novo are "granted." Calling a cleared device approved is misbranding under 21 CFR 807.97.
What is a Class 2 medical device?
A Class II device carries moderate risk, between Class I and Class III. Most need a 510(k) showing substantial equivalence to a predicate before sale, though some Class II types are exempt. Apple's hypertension notification feature is a recent example.
Can you market a medical device before FDA clearance?
You can advertise and display a device with a pending 510(k) under FDA's long-standing compliance policy, but you cannot take orders or be prepared to take orders. Investigational devices cannot be promoted or test marketed at all. Build a waitlist and press relationships, then open sales on clearance day.
Is a wellness device a medical device?
Not if its intended use is general wellness only and it is low risk, under FDA's January 2026 guidance. Sleep, fitness, stress or weight claims with no disease reference generally qualify. Disease references, clinical thresholds, clinical-action alerts or "medical grade" claims take a product out of the wellness lane.
How long does it take to launch a medical device?
It depends on the pathway. FDA says a 510(k) decision usually comes within 90 days and sets a goal of 150 review days for De Novo, excluding time on hold. Design, testing, any clinical study and payer coverage come on top.
What does a medical device marketing agency do?
It builds the commercial launch around the regulatory path: positioning, claims language inside the intended use, the website and store, PR, campaigns and launch sequencing. It does not replace regulatory consultants or counsel, who own the FDA submission.
What is a medical device distributor?
A distributor buys, stores and resells devices to hospitals, clinics, pharmacies or retailers. In hospital purchasing, group purchasing organizations negotiate contracts for many providers at once. Consumer devices sold direct can skip distributors until retail demand justifies them.
